Please login to the form below

Not currently logged in
Email:
Password:

S-A agrees malaria research project

Sanofi-aventis and Medicines for Malaria Venture (MMV) are to work together on Orthology Malaria – a project to research malaria treatments

Sanofi-aventis (S-A) and Medicines for Malaria Venture (MMV) have signed an agreement to research malaria treatments.

The three-year research project agreement, called Orthology Malaria, aims to develop drug candidates from a set of S-A's compounds that have been selected for their potential activity against malaria parasites.

Each stage of the project will be evaluated by the S-A/MMV joint steering committee and assessed according to MMV's criteria for compound progression.

Dr Elias Zerhouni, president of global research and development at S-A, said: "Sanofi-aventis has a long standing history in the pursuit of novel anti-malarial compounds, which are essential to save the lives of more than 750,000 people annually.

"This new partnership will enable us to mobilise each organisation's expertise, resources and know-how to identify novel medicines for malaria patients."

As discussed in PME's interview with Gilles Lhernould, senior vice president corporate social responsibility at S-A, the company has previously worked with MMV to conduct a pharmocovigilance study in sub-Saharan Africa concerning the safety and efficacy of anti-malarial drug artesunate-amodaquine.

MMV also signed a deal with AstraZeneca in June, 2010, to identify novel candidate drugs for the treatment of malaria, and worked with the Novartis Institute for Tropical Diseases to develop malaria drug spiroindolone NITD609.

5th May 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Clark Health Communications

Clark Health Communications (CHC) is an independent, award-winning health and medical communications agency. Our collaboration with experts and advocates enhances...

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe’s leading hub for life sciences innovation...

Infographics